LONG-TERM SURVIVAL AFTER RADIOTHERAPY ALONE: RADIATION THERAPY ONCOLOGY GROUP PROSTATE CANCER TRIALS
作者： MACK ROACH , JIANDONG LU , MILJENKO V. PILEPICH , SUCHA O. ASBELL , MOHAMMED MOHIUDDIN
DOI: 10.1016/S0022-5347(01)61793-2
关键词: Prostate cancer 、 Medicine 、 Hormonal therapy 、 Malignancy 、 Oncology 、 Radiation therapy 、 Prostate neoplasm 、 Survival rate 、 Internal medicine 、 External beam radiotherapy 、 Clinical trial
摘要: AbstractPurpose: We assess the relative importance of several pretreatment characteristics in predicting death from prostate cancer patients treated with curative intent external beam radiotherapy alone.Materials and Methods: Patients entered on 4 prospective phase III randomized trials conducted by Radiation Therapy Oncology Group between 1975 1992 were selected for this analysis if they deemed evaluable eligible trial, had received no hormonal therapy initial treatment followup information was available. A disease specific survival event declared certified as due to cancer, complications or unknown causes clinically active malignancy. Median early late studies exceeded 11 6 years, respectively.Results: Most (1,557) tumors staged at T3 (59%), 87 (36%) T1-2 pathologically positive lymph nodes. On multiva...
jurology.com 参考文章(29)
M. Roach, Is race an independent prognostic factor for survival from prostate cancer Journal of The National Medical Association. ,vol. 90, ,(1998)
Bagshaw Ma, Ray Gr, Cox Rs, Status of radiation treatment of prostate cancer at Stanford University. NCI monographs : a publication of the National Cancer Institute. ,vol. 7, pp. 47- 60 ,(1988)
M V Pilepich, R Caplan, R W Byhardt, C A Lawton, M J Gallagher, J B Mesic, G E Hanks, C T Coughlin, A Porter, W U Shipley, D Grignon, Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Journal of Clinical Oncology. ,vol. 15, pp. 1013- 1021 ,(1997) , 10.1200/JCO.1997.15.3.1013
G. Aus, J. Hugosson, L. Norlen, Long-term Survival and Mortality in Prostate Cancer Treated with Noncurative Intent The Journal of Urology. ,vol. 154, pp. 460- 465 ,(1995) , 10.1016/S0022-5347(01)67074-5
Gerald Hanks, Alexandra Hanlon, Wayne Pinover, Margie Hunt, Benjamin Movsas, Timothy Schultheiss, 115 Dose escalation with 3-D CRT in prostate cancer: Five year dose responses and optimal treatment International Journal of Radiation Oncology Biology Physics. ,vol. 39, pp. 192- ,(1997) , 10.1016/S0360-3016(97)80672-4
PATRICIA M. GRAMBSCH, TERRY M. THERNEAU, Proportional hazards tests and diagnostics based on weighted residuals Biometrika. ,vol. 81, pp. 515- 526 ,(1994) , 10.1093/BIOMET/81.3.515
Anthony L. Zietman, Katherine C. Dallow, Patricia A. McManus, Niall M. Heney, William U. Shipley, Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease Urology. ,vol. 47, pp. 236- 239 ,(1996) , 10.1016/S0090-4295(99)80423-3
Gerald E. Hanks, W.Robert Lee, Alexandra L. Hanlon, Margie Hunt, Edward Kaplan, Barry E. Epstein, Benjamin Movsas, Timothy E. Schultheiss, Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml International Journal of Radiation Oncology Biology Physics. ,vol. 35, pp. 861- 868 ,(1996) , 10.1016/0360-3016(96)00207-6
M.V. Pilepich, J.M. Krall, W.T. Sause, R.J. Johnson, H.H. Russ, G.E. Hanks, C.A. Perez, M. Zinninger, K.L. Martz, Prognostic factors in carcinoma of the prostate— analysis of rtog study 75-06 International Journal of Radiation Oncology Biology Physics. ,vol. 13, pp. 339- 349 ,(1987) , 10.1016/0360-3016(87)90007-1
David P. Byar, F. K. Mostofi, , Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies Cancer. ,vol. 30, pp. 5- 13 ,(1972) , 10.1002/1097-0142(197207)30:1<5::AID-CNCR2820300103>3.0.CO;2-S